AUTHOR=Hong Qing , Wang Jidong , Zhang Huayue , Liu Xiaoming , Liu Zhenmin 

TITLE=Study of the effect of Lactobacillus crispatus FSCDJY67L3 on Helicobacter Pylori eradication: a double-blind randomized controlled clinical trial

JOURNAL=Frontiers in Immunology

VOLUME=14

YEAR=2023

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1265995

DOI=10.3389/fimmu.2023.1265995

ISSN=1664-3224

ABSTRACT=<p><italic>Helicobacter pylori</italic> (<italic>H. pylori</italic>) is a gram-negative bacterium exhibiting high pathogenicity. Traditional antibiotic treatments are considered ineffective as the <italic>H. pylori</italic> resistance has increased. Recently, a quadruple therapy strategy of probiotics and antibiotics to eliminate <italic>H. pylori</italic> was proposed. Probiotics play a therapeutic role as supplements in this process. The present research screened a probiotic strain (<italic>Lactobacillus crispatus</italic> FSCDJY67L3) that co-aggregates strongly with <italic>H. pylori</italic>. <italic>L. crispatus</italic> FSCDJY67L3 was demonstrated to significantly reduce <italic>H. pylori</italic> load (<sup>14</sup>C breath test) in clinical trials with <italic>H. pylori-</italic>positive patients. The Gastrointestinal Symptom Rating Scale (GSRS) score decreased, indicating improvement in the gastrointestinal discomfort of patients. Furthermore, <italic>L. crispatus</italic> FSCDJY67L3 showed no change in the structure of the intestinal flora of patients. Routine blood indices and blood biochemical indices related to liver and kidney function were also not affected in the patients. Therefore, <italic>L. crispatus</italic> FSCDJY67L3 may be used clinically as a supplement for the treatment of <italic>H. pylori</italic>.</p><sec><title>Clinical Trial Registration</title><p><uri xlink:href="https://www.chictr.org.cn/" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.chictr.org.cn/</uri>, Chinese Clinical Trial Registry (ChiCTR2100053710).</p></sec>